HC@AIxIA: AI&Health Seminar Series (2025) - FEBRUARY 13

[*apologize for multiple postings*]

Dear Madam/Sir,

This is to officially announce the SECOND seminar of the "*AI & Health:
Seminars 2025*" series as hosted by HC@AIxIA, i.e., the "Artificial
Intelligence for Healthcare" working group of the Italian Association for
Artificial Intelligence.


*    *** Save the date: 13 FEBRUARY 2025. 3:30 CET ****
We hope you will attend and participate in the discussion on the relevant
topics that will be presented and by our speakers.
*Feel free to share this with those potentially interested.*


*Link for participating: https://bit.ly/hc-2025-02
<https://bit.ly/hc-2025-02> *(PLEASE CHECK the site
https://aixia.it/en/gruppi/hc/ for any changes or updates) - Please find
some details below, and a poster attached.



*== February 2025 seminar ==**2025 February 13 - 3:30PM CET*

*Anna Lavizzari, MD, MSc, *Attending Physician - S.C. di Neonatologia e
Terapia Intensiva Neonatale, Fondazione IRCCS Cà Granda Ospedale Maggiore
Policlinico, Milano, Italy

*Title*: The context around artificial intelligence in medicine: the model
of Bronchopulmonary Dysplasia and Post-prematurity Respiratory Disease

*Abstract*: Preterm infant survival has dramatically increased in the last
decades, including those infants born at very low gestational age/at the
limit of viability. However, the rate of Bronchopulmonary dysplasia (BPD)
has increased. BPD is one of the most worrisome complications of
prematurity and the most common chronic respiratory disorder of early
childhood. Infants with BPD present respiratory sequelae in early
childhood, including wheezing, recurrent respiratory infections,
re-hospitalization, need for home- oxygen and inhaled therapy. During
adolescence, they still present with airway obstruction symptoms, exercise
fatigue, and an early decline in lung function toward Chronic Obstructive
Respiratory disease has been described in early adulthood. The BPD
pathogenesis is complex and multifactorial. It includes 1) the premature
arrest of lung development, 2) the antenatal exposure to
infection/inflammation, growth restriction and smocking; 3) post-natal
exposure to invasive/non-invasive respiratory support and supplemental
oxygen, post-natal infections/inflammation and poor nutrition; 4) genetic
predisposition. The formal diagnosis of BPD is assessed at 36 weeks
post-menstrual age, and it is currently based on the degree of respiratory
support required at that time point. However, the window for intervention
(preventive strategies and pharmacological interventions) occurs in the
first days of life. Diagnostic tools for early identification of infants at
risk are currently lacking, due to both the vulnerability of this
population and the lack of suitable lung function testing. Artificial
intelligence has the potential for early identification and stratification
of the population at risk, offering the opportunity for targeted therapy
and more accurate prognostic prediction.

*Short Bio*: Anna Lavizzari is a consultant neonatologist at the Neonatal
Intensive Care Unit of Fondazione IRCCS Cà Granda Ospedale Maggiore
Policlinico – Milan, Italy. Her clinical research has focused on lung
recruitment strategies at birth, neonatal non-invasive respiratory support,
Forced Oscillation Technique for assessing respiratory mechanics,
individualized surfactant therapy, respiratory support optimization and
lung function follow-up of former preterm infants. She did a research
fellowship at the Murdoch Children’s Research Institute, Melbourne
(2013-2014) with Dr D Tingay and Dr P Dargaville. She has participated in
experimental research on the long-term respiratory complications in former
preterm lambs (Dr J Pillow, University of Western Australia, and Dr K
Albertine, University of Utah). She served as secretary (2019-2021) and
chair (2022-2024) of the Pediatric and Neonatal Intensive Care group of the
European Respiratory Society. She is a member of the Pulmonology Board of
the Italian Society of Neonatology (SIN) and a member of the Pulmonology
section of the European Society for Paediatric Research (ESPR).

*Flyer*:
https://drive.google.com/open?id=1-S7_FHkpFtm1mdBZK9fZpY9WBiFJ3htm&usp=drive_fs

*Link to participate*: https://bit.ly/hc-2025-02
(PLEASE CHECK the site https://aixia.it/en/gruppi/hc/ for any changes or
updates)

====

Some notes
Serving as coordinators of the working group on AI for Healthcare of the
Italian Association of Artificial Intelligence (AIxIA, see:
https://aixia.it/en/gruppi/hc/), part of our commitment consists of
fostering contamination and collaboration between AI researchers and
experts and operators in Medicine and Healthcare; in particular, we aim to
contribute in building a two-way road for informing healthcare operators
about AI results and opportunities, while also raising awareness among AI
researchers about challenges and problems in medicine and healthcare.
Therefore, the 2025 seminar series, in the trail of the 2024 edition, will
feature a number of experts presenting research results, projects, best
practices, ideas, and more to a mixed audience of AI researchers and
healthcare operators.

== Are you interested in Joining the group? ==
Please head to https://aixia.it/en/gruppi/hc/ fo find out how. Do not
hesitate to contact us at hc-aixia@googlegroups.com for any information or
clarification.


Thank you for your interest in the AI & Health seminar series and the
HC@AIxIA working group, and see you soon!

Sincerely,
Francesco Calimeri, Mauro Dragoni, Fabio Stella
(coordinators of the HC@AIxIA working group)



[image: HC@AIxIA - Seminars AI & Health 2025 - Locandina 02 febbraio.png]